NASDAQ$EOLS
Evolus Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Net Revenue grew 235% Year-over-Year and exceeded Annualized Revenue Run Rate Goal.
Evolus reported a record level of sales in Q2 2021, with net revenues increasing by 235% year-over-year to $26.1 million. The company exceeded its annualized revenue run rate goal of $100 million and had a strong cash position of $131.7 million at quarter-end. Evolus is on track for a European launch in early 2022.
- Jeuveau® net revenues were $26.1 million, up strongly compared to the second quarter of 2020, driven primarily by higher volumes.
- Increased Jeuveau® purchasing account base to more than 6,000 customers.
- Over 200,000 consumers registered in the Evolus customer loyalty program as compared to 122,000 at year-end 2020, a 66% increase.
- On track for European launch in early 2022, representing an estimated $470 million botulinum toxin market in 2022 in which the company will compete.
Headline financials
Revenue & EPS history
Evolus · Revenue · Quarterly
$26.1M
Forward guidance
The company increased its full year 2021 adjusted gross profit margin target to a range of 54% to 57%. Beginning in the fourth quarter of 2022, the gross profit margin is expected to exceed 70% due to reduced settlement royalty rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+0.5%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+35.4%
Q4 2025
Best reaction
-26.9%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | +19.3% | — | |
| Q4 2025 | +35.4% | +29.5% | -2.4% | |
| Q3 2025 | +5.4% | +2.6% | +0.6% | |
| Q1 2025 | -14.2% | -13.9% | -14.6% | |
| Q4 2024 | -1.3% | -11.6% | -25.5% | |
| Q3 2024 | -13.3% | -20.4% | -23.2% | |
| Q2 2024 | +15.2% | +9.2% | +30.4% | |
| Q1 2024 | -1.0% | -4.8% | -7.4% | |
| Q4 2023 | -0.3% | -0.1% | -6.0% | |
| Q3 2023 | +9.7% | +0.4% | +20.3% | |
| Q2 2023 | -1.2% | -8.3% | -2.6% | |
| Q1 2023 | +17.8% | +14.9% | -3.9% | |
| Q4 2022 | -6.4% | -7.7% | -8.5% | |
| Q3 2022 | -8.4% | -3.2% | -1.6% | |
| Q2 2022 | -26.9% | -28.3% | -30.3% | |
| Q1 2022 | +9.2% | +29.0% | +20.4% | |
| Q4 2021 | +1.8% | +3.0% | +25.0% | |
| Q3 2021 | -9.5% | -10.0% | -33.3% | |
| Q2 2021 | -6.9% | +1.7% | -15.1% | |
| Q1 2021 | -0.9% | +2.4% | +41.1% | |
| Q4 2020 | -21.1% | -28.2% | -43.0% | |
| Q3 2020 | -1.9% | +2.3% | +23.9% | |
| Q2 2020 | +6.6% | +6.0% | +2.6% | |
| Q1 2020 | +4.8% | -9.7% | +32.9% | |
| Q4 2019 | -3.4% | -8.1% | -51.9% | |
| Q3 2019 | -2.2% | -10.7% | -20.3% | |
| Q2 2019 | -10.9% | -21.8% | -6.7% | |
| Q1 2019 | -7.5% | -5.1% | -46.4% | |
| Q4 2018 | +7.0% | -3.3% | -2.7% | |
| Q3 2018 | -5.8% | -6.6% | -10.6% | |
| Q2 2018 | +6.0% | +8.2% | +34.8% | |
| Q1 2018 | +27.9% | +38.9% | +142.4% | |
| Q4 2017 | +8.5% | +9.1% | -15.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro